Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 46

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

278

HTML

1996

Figures (1-2)

248

Tables (1-2)

202

Sum=2724

Dec 14, 2007 (publication date) through Nov 8, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Dec 14, 2007; 13(46): 6231-6235
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6231

Full Size Figure Download Figure

Figure 1 PFS curve. Median PFS was 3.9 mo (95% CI: 2.0-8.7).

Citation: Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol 2007; 13(46): 6231-6235
URL: https://www.wjgnet.com/1007-9327/full/v13/i46/6231.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i46.6231